Research Australia supports TGA Reforms

The Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 (the Bill) is part of the Government’s response to the recommendations of the review of Medicines and Medical Devices Regulation (MMDR), and the legislation is supported by Research Australia’s submission to the inquiry by the Senate Standing Committees on Community Affairs.

The aim of the Review’s recommendations is to improve the processes for the approval of medicines and medical devices by the Therapeutic Goods Administration. Together the regulatory reforms are expected to reduce the administrative burden on applicants and make the approval process faster without jeopardising the safety of consumers.

Achieving this aim will provide consumers with earlier access to potentially lifesaving new medicines and devices. It is also an effective means of supporting Australia’s medical device and medicines industries; by accelerating their pathway to market it will enable them to become profitable more quickly, providing them with more resources to pursue the international markets needed to be truly successful and profitable.

Research Australia submission TGA Bill

Victorian Medical Technology and Pharmaceuticals Strategy

Research Australia has responded to the Victorian Governments’ discussion paper on the Victorian medical technologies and pharmaceuticals sectors, proposing the Victoria capitalise on its existing expertise in health and medical research and significant infrastructure to take advantage of future growth in this sector. There is significant scope of the Victorian Government to complement and take advantage of the Australian Government’s focus on the sector as a priority area for investment.

Victorian Medical Technology and Pharmaceuticals Strategy